Vaxcyte Inc
For the period ended Dec 31, 2024. Filed Feb 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 25, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.
| Vaxcyte, Inc. | ||
| Date: February 25, 2025 | By: | /s/ Grant E. Pickering |
|---|---|---|
| Grant E. Pickering | ||
| Chief Executive Officer | ||
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Grant E. Pickering and Andrew Guggenhime, and each of them, as his or her true and lawful attorneys-in-fact, each with full power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the SEC, hereby ratifying and confirming all that each of said attorneys-in-fact or their substitute or substitutes may do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Grant E. Pickering | Chief Executive Officer and Director | February 25, 2025 |
| Grant E. Pickering | (Principal Executive Officer) | |
| /s/ Andrew Guggenhime | President and Chief Financial Officer | February 25, 2025 |
| Andrew Guggenhime | (Principal Financial Officer) | |
| /s/ Elvia Cowan | Senior Vice President, Finance | February 25, 2025 |
| Elvia Cowan | (Principal Accounting Officer) | |
| /s/ Carlos Paya | Director | February 25, 2025 |
| Carlos Paya, M.D., Ph.D. | ||
| /s/ Annie Drapeau | Director | February 25, 2025 |
| Annie Drapeau | ||
| /s/ John Furey | Director | February 25, 2025 |
| John Furey | ||
| /s/ Halley Gilbert | Director | February 25, 2025 |
| Halley Gilbert | ||
| /s/ Peter Hirth | Director | February 25, 2025 |
| Peter Hirth, Ph.D. | ||
| /s/ Jacks Lee | Director | February 25, 2025 |
| Jacks Lee | ||
| /s/ Teri Loxam | Director | February 25, 2025 |
| Teri Loxam | ||
| /s/ Heath Lukatch | Director | February 25, 2025 |
| Heath Lukatch, Ph.D. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.